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Abstract
Approximately 95% of patients receiving radiotherapy (RT) will 
ultimately develop radiation-induced dermatitis (RID) during 
or after the course of treatment, with major consequences on 
quality of life and treatment outcomes. This paper reviews the 
pathophysiology of RID and currently used topical products 
for the prevention and treatment of RID. Although there 
is no consensus on the appropriate management, recent 
evidence suggests that the use of topical products supports 
to protect and promote tissue repair in patients with RID. Basic 
recommendations include advice to wear loose clothing, using 
electric razors if necessary, and avoiding cosmetic products, 
sun exposure or extreme temperatures. Based on mechanisms 
involved and on the clinical characteristics of oncological 
patients, the profile of the ideal topical product for addressing 
RID can be designed; it should have limited risk of adverse 
events, systemic adsorption and drug–drug interactions, should 
be characterized by multiple clinical activities, with a special 
focus on localized pain, and should have a careful formulation as 
some vehicles can block the RT beam.
Keywords: pain, quality of life, radiation-induced dermatitis, 
radiotherapy, skin toxicity, topical treatment.
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Introduction
Radiation-induced dermatitis (RID) is a very common side 
effect that is almost universally experienced by patients 
undergoing radiotherapy (RT) for cancer treatment. RID results 
from cutaneous or subcutaneous lesions due to external beam 
radiation. Indeed, it has been estimated that approximately 
95% of patients receiving RT will ultimately develop RID  
during or after the course of treatment, with major 
consequences on quality of life and adherence to RT 
treatments, thereby affecting clinical outcomes.1–3  
However, at present, there is no consensus on the  
appropriate management of this condition. Therefore, there  
is urgent need for increased knowledge to guarantee a  
range of therapeutic options available for the treatment  
of RID.1
Recent evidence suggests that topical products may be used 
to protect and promote tissue repair in patients with RID, 
including within the prophylactic setting.4,5
The aim of this paper is to discuss current knowledge on RID 
and propose targets for the prevention/treatment of this 
condition. On these bases, the characteristics of the ‘ideal’ 
compound to address this side effect will be described.
Manuscripts for consideration in the present paper were 
retrieved via a PubMed search, using pertinent keywords  
(e.g. radiation-induced dermatitis). Papers were then selected 
for inclusion according to their relevance to the topic, as 
judged by the authors. The reference lists of the papers were 
also browsed to identify other suitable publications. Papers 
from personal collections of literature of the authors were also 
considered.
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RID: basic concepts
Clinical manifestations
Key symptoms of RID include pain, ulceration, swelling, 
itching, burning, and physical and psychological discomfort. 
Opportunistic infections may also arise.6–9 While these lesions 
may resolve over time, they can deeply influence quality of 
life and also limit the duration of treatment and the dose of 
radiation delivered, all of which have important consequences 
on therapy outcomes.4,10
The severity of RID is usually assessed by the physician 
according to standard instruments, such as the Common 
Terminology Criteria for Adverse Events (CTCAEs) scale (versions 
2.0, 3.0, 4.0, or 4.03) or the Radiation Therapy Oncology  
Group/European Organization for Research and Treatment 
of Cancer (RTOG/EORTC) scale.2 However, patient-reported 
outcome (PRO) tools (e.g. Skindex-16 or Brief Pain Inventory 
[BPI]) are sometimes used in clinical practice together with the 
CTCAE scale.2 Up to 90% of patients will develop mild (grade 1) 
skin reactions, and approximately 20% of patients will develop 
severe forms of this condition.11 Remarkably, concomitant 
systemic treatments (e.g. platinum-based regimens, cetuximab, 
5-fluorouracil), administered to a good proportion of patients 
undergoing RT, can enhance the severity of RID.2
RID is characterized by an acute reaction when it occurs around 
the time of therapy and either chronic or late onset when 
it appears months or years after the end of treatment. Early 
skin reactions to RT usually occur within days to weeks from 
initiation, while late changes can happen even months or years 
after the completion of a RT course.
Usually, an acute phase of RID is defined by skin lesions that 
appear within 90 days from the start of treatment. Injury can 
first manifest as a transient erythema that may be reported as 
early as within the first 24 hours after the initiation of RT and 
is resolved within a few days (Figure 1).12,13 Later, during weeks 
2–4 of therapy, a more sustained generalized erythema and 
the onset of pain may be reported often associated with other 
skin changes, such as dryness and hyperpigmentation. During 
weeks 3–6 (from the start of therapy), dry desquamation 
associated with pain, pruritus, and scaling can develop if 
the cumulative radiation dose reaches 20 Gy, and moist 
desquamation may occur if total radiation dose to the skin is 
≥40 Gy.14 In this latter case, temporary interruption of RT, until 
the area is able to re-epithelialize, may be necessary.15
Chronic skin reactions to RT develop more than 90 days after 
the completion of radiation treatment.12 These reactions 
include vascular injury resulting in telangiectasia, epidermal 
thinning, dermal atrophy, pigmentation, fibrosis, edema, 
keratosis, and, even, dermal necrosis. Moreover, patients show 
increased risk for the development of non-melanotic cutaneous 
malignancies in the course of their life.
Pathophysiology
Injury from RT derives from the generation of free radicals 
and reactive oxygen species in the rapidly dividing cells of 
Figure 1. Progression of clinical manifestations and symptoms of RID.
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the basal layer and underlying dermis.12 Within a few hours 
from the start of treatment, this action decreases the number 
of functional stem cells, induces changes in endothelial cells, 
and promotes inflammation by the release of several cytokines 
and chemokines, most notably interleukin (IL)-1α, IL-1β, tumor 
necrosis factor-α, IL-6, IL-8, C–C motif chemokine ligand 4 
(CCL4), C–X–C motif chemokine ligand 10 (CXCL10), and C–C 
motif chemokine ligand 2 (CCL2).15,16 Over the subsequent 
2–4 weeks, a sustained generalized erythema develops, most 
likely associated with local degeneration and edema, resulting 
from infiltration of leukocytes into the irradiated skin, which 
is a ‘hallmark’ of radiation-induced skin injury. Dryness and 
epilation, often observed at this time of the course of RID, 
result from the destruction of sebaceous glands and hair 
follicles.17–19
Moreover, differing from other forms of mechanical or chemical 
damage to the skin, RT-induced damage is repetitive and 
accumulates over the course of treatment, leading also to a 
delayed disruption of the epidermal barrier. Indeed, chronic 
effects induced by RT comprise changes of the vasculature and 
connective tissue of the cutaneous and subcutaneous layers. 
Remodeling of epithelium may then lead to the formation of 
telangiectasias.20 With accumulating doses of radiation, if the 
healing process based on growth factors, such as fibroblast 
growth factor (FGF) or epidermal growth factor (EGF), is 
impaired,21 melanocytes and fibroblasts can be destroyed, 
causing hypopigmentation and atrophy of the derma.12
Epidemiology of RID
RID is a widespread, although often neglected, side effect of RT. 
Indeed, at least 50% of patients with any type of cancer receive 
some form of RT during their disease history.4 This prevalence is 
even higher in patients with head and neck and breast cancer: 
it has been estimated that 80–90% of all patients with head 
and neck cancer receiving RT develop RID, and 25% develop 
severe skin reactions.22 In the breast cancer setting, one of the 
most widespread forms of cancer worldwide, 45% of patients 
receive RT, and the wide majority of them (74–100%) report 
RID.23 Furthermore, chronic RID develops in one out of three 
patients and can appear up to 10 years after the completion of 
RT.24 As >80% of all women treated for breast cancer survive for 
≥10 years, the burden of chronic RID is mounting.25 The risk of 
developing RID depends on various treatment-related factors: 
the radiation dose during a single delivery, the total dose, the 
duration of exposure, the volume of the treated area, and the 
combination with other therapies, such as chemotherapy.26 
Furthermore, RID can be influenced by patient-related factors 
that include high body mass index (BMI), smoking, nutritional 
status, pre-existing skin diseases, such as psoriasis, and genetic 
susceptibility.
Skin damage has also been associated with chemotherapy, 
although incidence of this event has not been precisely 
estimated.26 Of note, radiation recall dermatitis is an acute 
inflammatory skin reaction occurring in a skin area previously 
exposed to RT and triggered by subsequent intake of a drug, 
most commonly a chemotherapeutic agent. The incidence of 
radiation recall dermatitis cannot be precisely determined, as 
most evidence comes from case report studies. Nevertheless, 
the effect has been reported in association with the use of 
several antineoplastic drugs.27
The rationale and bases for 
management of RID
As of today, management of RID is still based on preliminary 
evidence.4 Indeed, at present, it is not possible to propose any 
firm recommendation to prevent or reduce RID.2,4,20,28,29
However, some basic recommendations can be made, 
according to the Multinational Association of Supportive Care 
in Cancer (MASCC) guidelines20: patients should be advised to 
wear loose clothing, use electric razors (if necessary), and avoid 
cosmetic products, sun exposure or extreme temperatures.12 
Moreover, regular skin care assessment is mandatory during RT 
treatments.
In multimorbid, often polytreated and frail patients, like 
many in the oncological population, topical substances 
may represent the best initial option for treatment of skin 
toxicity.1,30–32
It is commonly accepted that daily topical treatment could be 
useful if started right from the beginning of RT to prevent the 
onset of RID.4
Available information on currently used topical approaches for 
the prevention and treatment of RID is presented in Table 1,  
while an overview of those approaches is presented in the 
following section.
Different treatments for RID: an 
overview
Washing
Following standard hygiene practices is undoubtedly the most 
advantageous choice in the management of RID. Two well-
conducted randomized controlled trials (RCTs) showed that 
washing with mild soap and lukewarm water reduces itching 
and RID severity.33,34
Dressings
Silver sulfadiazine, a topical antibacterial, is used as cream 
for second- and third-degree burns. This molecule is also 
endowed with anti-inflammatory properties and barrier-
enhancing functions, thereby contributing to protect the skin 
from infectious agents.1 In a preliminary study, the use of silver 
sulfadiazine–containing dressing was associated with a lower 
total severity of RID.35 Similar findings were reported for silver 
nylon dressing36,37 or for Mepilex Foam Lite dressing.38
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Table 1. Topical approaches currently used for the prevention and treatment of RID.
Study Study design Setting Patients (n) Treatments Main outcomes
Campbell, 
199233
RCT Adjuvant RT of 
breast or chest
99 1. No washing
2. Washing with water
3.  Washing with water 
and soap
Lower acute skin reaction in 
washing groups
Roy, 200134 RCT RT for breast cancer 99 1. No washing
2.  Washing with water 
and soap
Moist desquamation in 33% 
of no washing and 14% of 
washing groups; higher scores 
for pain, itching, burning in no 
washing
Hemati, 
201235
RCT RT for breast cancer 102 1.  Silver sulfadiazine 
1% three-times/day, 
for 5 weeks
2. Controls
Median total score of skin 
injury: 
  •  Group 1: 5.49 
  •   Control: 7.21 in controls
Niazi, 
201236
RCT Rectal or anal cancer 42 1.  Silver clear nylon 
dressing
2. Standard skin care
Mean dermatitis score: 
  •  Group 1: 1.67 
  •  Standard of care: 2.53
Aquino-
Parsons, 
201037
RTC Breast RT 196 1.  Silver clear nylon 
dressing
2. Standard skin care
No difference in incidence and 
size of moist desquamation 
and skin toxicity score
Zhong, 
201338
RCT Nasopharyngeal 
carcinoma patients 
with radiodermatitis
88 1.  Mepilex Foam Lite 
dressing
2. Usual care
Healing time:
  •  Group 1: 16 days 
  •  Group 2: 23 days
Haruna, 
201740
Meta-analysis Breast cancer 845 1.  Topical 
corticosteroids
Reduced incidence of wet 
desquamation in treated 
patients
Ho, 201841 RCT Breast cancer 124 1.  0.1% mometasone 
furoate
2.  Eucerin original 
cream
Moist desquamation:
  •  Group 1: 43.8% 
  •  Group 2: 66.7%
Lower incidence of skin 
toxicity; later occurrence of 
grade 3 dermatitis
Ghasemi, 
201946
RCT Breast cancer 70 1.  Topical 1% 
atorvastatin
2. Placebo
Atorvastatin reduced swelling, 
itching, and pain
Wells, 
200448
RCT Head and neck, 
breast or anorectal 
cancer
357 1. Aqueous cream
2. Sucralfate cream
3. No cream
No differences among groups 
in severity of skin reaction
Falkowski, 
201149
Open Breast cancer 21 1% sucralfate lotion No radiodermatitis prevention
Elliott, 
200650
Phase III RCT Carcinoma of oral 
cavity, pharynx, or 
larynx
547 1.  Prophylactic 
trolamine emulsion
2.  Interventional 
trolamine emulsion
3.  Institutional 
preference
No benefit of trolamine tor 
incidence of radiodermatitis 
or quality of life
Fenig, 
200151
RCT Breast cancer 74 1. Biafine
2. Lipiderm
3. No treatment
No advantage in any group to 
gaps in RT, patient impression, 
and skin reaction
Gosselin, 
201052
RCT Breast cancer 208 Trolamine cream 
versus placebo
No reduction of RT incidence
(Continued)
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Table 1. (Continued)
Study Study design Setting Patients (n) Treatments Main outcomes
Abbas, 
201253
Phase III Head and neck 
cancer
30 1. Trolamine emulsion
2. Usual care
Grade 3 skin reaction  
in 20% of group 1 and 53% of 
group 2
Imai, 201490 RCT Head and 
neck cancer, 
chemoradiotherapy
40 1.  p-Hydroxy-p-
methyl butyrate/
arginine/glutamine 
supplementation
2. No supplement
No difference in incidence of 
G3 dermatitis
Kang, 
201457
Observational Cancer patients 
receiving >50 Gy
1172 EGF-based cream Incidence of radiodermatitis 
was 46.6%, 18.0%, 5.5%, 
and 0.9% from grade 1 to 4, 
respectively
Kouvaris, 
200158
Open study Vulvar carcinoma 61 1. Steroid cream
2.  Steroid cream + 
GM-CSF
Reduced score of skin 
reactions and duration of RT 
interruptions
Chan, 
201479
RCT RT for cancer 174 1. Allantoin emulsion
2. Aqueous cream
Allantoin emulsion is  
less effective than an  
aqueous cream on 
radiodermatitis
Heggie, 
200260
RCT Breast cancer 225 1. Aloe vera gel
2. Aqueous cream
Aqueous cream was better in 
reducing dry desquamation 
and pain
Geara, 
201862
Randomized, 
open-label 
study
Breast cancer 161 1.  p-sitosterol 
ointment
2. Trolamine cream
No difference in grade 2 and 3 
dermatitis
Pommier, 
200464
RCT Breast carcinoma 254 1.  Topical Calendula 
officinalis
2. Topical trolamine
Reduced incidence of grade 2 
dermatitis in group 1
Schneider, 
201565
RCT Head and neck 
cancer
51 1.  Topical Calendula 
officinalis
2.  Topical essential 
fatty acids
The incidence of grade 2 
dermatitis was higher in  
group 2
Zhao, 
201575
Single-arm 
trial
Breast cancer 24 Epigallocatechin-3-
gallate solution
Grade 2 dermatitis regression 
was observed in 2 patients
Zhu, 201676 Single-arm 
trial
Breast cancer 49 Epigallocatechin-3-
gallate solution
Reduced pain in 85% patients, 
burning in 89%, and itching in 
87% of patients 
Liguori, 
199770
RCT Head and neck, 
breast or pelvic 
cancer
152 1.  Hyaluronic acid 
cream
2. Placebo
Better global efficacy 
judgment by physician and 
patient for hyaluronic acid
Franco, 
201472
Single-arm 
observational 
study
Head and neck 
cancer
28 Hypericum perforatum 
and neem oil
Reduction of grade of 
radiodermatitis
Manas, 
201580
RCT Chemoradiation 
in head and neck 
cancer and breast 
cancer
98 1. Topical lactokine
2. Topical urea lotion
2 weeks after chemoradiation; 
67% of group 1 and 34% 
of group 2 were free of 
radiodermatitis
Cui, 201581 RCT Chemoradiation 
in nasopharyngeal 
carcinoma
96 1.   Olive oil during and 
after CRT
2  Placebo
Less severe dermatitis in 
group 1
(Continued)
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Table 1. (Continued)
Study Study design Setting Patients (n) Treatments Main outcomes
Palatty, 
201482
Two-arm 
open-label 
trial
Head and neck 
cancer
50 1.  Turmeric and sandal 
wood oil cream
2.  Usual care oil
Reduced grade of 
radiodermatitis al all time 
points in group 1
Shariati, 
202054
Double-blind 
RCT
RT for breast cancer 48 1. Doxepin (5%) cream
2.  Placebo 
Reduction of occurrence of 
acute dermatitis (grade 2 or 
higher)
Robijns, 
201839
RCT RT for breast cancer 120 1. Laser therapy
2. Placebo
Prevention of the 
development of acute 
dermatitis (grade 2 or higher)
Liao, 201943 RCT Radical RT in head 
and neck squamous 
cell carcinoma
41 1.  Mometasone 
furoate cream
2. No medication
Prevention of acute dermatitis 
when the radiation dose is 
<6000 cGY
Chan, 
201955
Single-blind, 
randomised 
controlled, 
superiority 
trial
Radical RT in head 
and neck cancer
197 1. StrataXRT®
2. 10% Glycerine 
(Sorbolene cream)
Prevention and delay of the 
development of skin toxicit 
(grade 2 and 3)
Zenda, 
201842
Double-arm, 
double-
blinded RC 
Phase III trial
Chemoradiotherapy 
for head and neck 
cancer
220 1. Topical steroid
2. Placebo
Not reported – ongoing
Note: CRT, chemoradiotherapy; GM-CSF, granulocyte–macrophage colony-stimulating factor; RCT, randomized controlled trial; 
RT, radiotherapy.
Laser therapy
Photobiomodulation therapy after the RT session twice a week 
was tested in breast cancer patients. The effectiveness of the 
treatment was evaluated by a quality-of-life questionnaire and 
results in a beneficial effect.39
Pharmaceuticals and biological agents
Topical corticosteroids are commonly prescribed for RID 
because of their ability to counteract the radiation-induced 
release of cytokines.32 While the efficacy of this therapeutic 
strategy is established in breast cancer40,41 and is currently 
under evaluation in head and neck cancer,42,43 the use of 
topical corticosteroids is frequently associated with the onset of 
clinically relevant adverse events.44 In particular, the prolonged 
use of steroids leads to skin thinning, which may be particularly 
contraindicated in this condition. Statins display some anti-
inflammatory, immunomodulatory, antioxidant, metabolic, 
and antibacterial properties and can have some efficacy in 
the reduction of severity of skin disorders, such as psoriasis, 
dermatitis, uremic pruritus, and vitiligo.45 In a preliminary 
experience, Ghasemi and colleagues investigated the topical use 
of atorvastatin.46
In topical formulation, sucralfate presents barrier abilities, 
antibacterial activity, anti-inflammatory effects, and 
angiogenesis-promoting capabilities.47 However, sucralfate 
did not reduce the severity of RID or improve patient-reported 
symptoms.48,49
Trolamine is extensively used for the management of RID, as it 
is supposed to function as a non-steroidal anti-inflammatory 
molecule.1 However, several RCTs did not show any  
advantage for trolamine over supportive care or even placebo 
in treating RD.50–53 Doxepin cream has been recently shown 
to prevent dermatitis when applied after RT in breast cancer 
patients.54
Silicone-based agents in vitro have been shown to regulate 
fibrosis and wound healing, although with potential  
practical inconvenience due to non-perfect adherence to the 
skin when bathing and in men with facial hair. StrataXRT®, a 
silicone-based film-forming agent, was shown to be  
effective in delaying the development of skin toxicity.55
EGF stimulates the proliferation of human epidermal stem 
cells, fibroblasts, and keratinocytes, thus contributing to skin 
lesion healing.56 Kang and colleagues suggested that topical 
EGF leads to a diminished incidence of toxicity when compared 
with historical data.57
Granulocyte–macrophage colony-stimulating factor  
(GM–CSF) promotes macrophage maturation and activity. 
When compared with patients receiving topical steroids  
alone, patients on topical steroids and GM-CSF-soaked  
gauze displayed reduced severity of RID and milder  
pain.58
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of skin damage caused by exposure to ultraviolet light.74 
In a phase I/II clinical trial, topical EGCG showed several 
beneficial effects.75,76
•	 Vitamins have also been tested in this setting. Ascorbic 
acid is endowed with powerful antioxidant and free 
radical-scavenging abilities. These characteristics led 
Halperin and colleagues to study the possible  
protective role of ascorbic acid in RID, but their study 
failed to demonstrate any benefit of topical ascorbic 
acid in this setting.77 Pantothenic acid (vitamin B5) has 
a central role in metabolism, and is essential for the 
integrity of normal skin. However, when compared  
with no treatment, a topical cream with pantothenic 
acid failed to show an enhanced protective effect 
against RID.78
•	 Topical preparations that contain comfrey extract, 
which comprises allantoin, may have some applications 
in the treatment of skin irritation. Indeed, in a double-
blind trial, patients assigned to the allantoin-containing 
cream had a lower severity of pain and itching at week 3 
compared with those on aqueous cream.79
•	 Lactokine is a protein derived from milk. In a pilot  
study, topical administration of a lactokine-containing  
product was effective in preventing and reducing 
the grade of RID in head and neck and breast cancer 
patients.80
•	 In an RCT on 94 patients with head and neck cancer, the 
acute RID that resulted was decreased in intensity with 
the application of olive oil.81 In another small randomized 
study on 50 patients, a cream containing turmeric and 
sandal wood oil was able to prevent the onset of RID, but 
the results require further validation in larger double-
blind trials.82
From bench to bedside: how to 
improve treatment of RID
RID has a major impact on quality of life of cancer patients 
and may interfere with oncologic therapies, thus reducing 
their effect.4 In particular, pain is perceived as among the 
most severe symptoms associated with RID,7 and also other 
symptoms experienced by patients – for example, itching and 
burning – are bothersome for patients.
From a basic research perspective, an improved understanding 
of the mechanisms of radiation-induced damage of the skin 
will lead to the opportunity to better schedule both preventive 
and curative strategies. Moreover, a large effort is needed to 
find predictive factors for the onset and severity of RID, also at a 
genomic level.2
It is of utmost importance to conduct proper epidemiological 
studies and nationwide surveys, with the aim to capture  
a clearer picture of incidence of RID and treatment  
approaches in different centers (e.g. primary versus referral 
centers).
Non-pharmaceutical agents
Several non-pharmaceutical agents have been proposed for 
the amelioration of RID. Here, we review the available topical 
treatments and one oral agent. The agents have been classified 
according to their main property. This does not exclude that 
one agent could present more than only one feature.
Anti-inflammatory agents
•	 Aloe vera is an anti-inflammatory herbal therapy 
endowed with protective and healing abilities.59 
However, despite these promising characteristics, aloe 
vera does not reduce the severity of RID.60
•	 Beta-sitosterol is a herbal formulation presenting 
antibacterial, analgesic, and anti-inflammatory 
effects.61 In a recent clinical trial, beta-sitosterol 
and trolamine were not associated with relevant 
improvements in RID, although the incidence of severe 
pruritus and local pain were both significantly reduced 
with beta-sitosterol.62
•	 Calendula officinalis has anti-inflammatory, antibacterial, 
antifungal, antioxidant, and angiogenic abilities.63 In 
an RCT, calendula significantly lowered the frequency 
of grade ≥2 acute dermatitis compared with trolamine 
(41 versus 63%, p<0.001). Moreover, patients assigned 
to calendula required fewer interruptions in RT and 
reported milder pain.64 These findings were confirmed in 
a more recent pilot randomized trial.65
•	 Hyaluronic acid (HA) is widely used in wound dressings, 
skin substitute products, and other applications in the 
field of regenerative medicine and dermatology.66,67 
HA is used in high-molecular weight and low-molecular 
weight forms, and the use of conjugated high- and low-
molecular weight HA can further increase the efficacy 
of this compound, in a synergic fashion.68 In vitro, HA 
protected fibroblasts from radiation damage,69 and in a 
double-blind RCT, HA was able to reduce the incidence 
of severe RID in 152 patients undergoing RT for head and 
neck, breast, or pelvic carcinomas.70 Recent evidence also 
supports the clinical use of HA for topical administration 
in patients with inflammatory conditions at the level of 
mucosa.71
•	 In a pilot study, Franco and colleagues prospectively 
evaluated the role of Hypericum perforatum and neem oil 
in the treatment of acute skin toxicity.72 This approach 
was preliminary and suggested to be safe and active in 
the management of this condition.
•	 Glutamine has been proposed to prevent oral RID and 
mucositis. However, a study evaluating the efficacy of oral 
glutamine showed no significant effect on the severity of 
oral mucositis.73
Antioxidant agents
•	 Catechins, in particular epigallocatechin-3-gallate (EGCG), 
present antioxidant activities that may promote healing 
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At present, there is no standard treatment for RID, and a more 
rational approach to the therapy of this condition has been 
advocated.4 Properly designed prospective studies, possibly 
RCTs, investigating RID should be conducted to collect high-
level evidence on this topic, which is currently lacking. These 
studies should contemplate PROs and quality-of-life measures 
as main outcome measures. An important pitfall is the lack of 
a reliable objective tool to measure RID. Methods used and 
reported in the literature are reflectance spectrophotometry, a 
non-invasive technique aimed at measuring cellular pigments, 
and trans-epidermal water loss (TEWL) measurement, to 
analyze the epidermal barrier function.83,84
To overcome current doubts and help clinicians in managing 
patients with RID, here we provide some practical tips that can 
be easily suggested to patients (Box 1).
The ideal therapy for RID should present a number of 
characteristics and be based upon a rational selection of 
components. First, cancer patients are in almost all cases 
polymedicated, and receiving a number of treatments 
associated with bothersome adverse events. Hence, a topical 
product for the therapy of RID, with limited risk of systemic 
adsorption and drug–drug interaction, may be preferred, in 
line with previous recommendations in the dermatological 
setting.30 Moreover, the product should address the 
complex array of manifestations of RID, and hence should be 
characterized by the combinations of a few selected active 
principles with different mechanisms of actions or targets 
and multiple clinical activities to counteract such diverse 
symptoms. Agents able to prevent the earlier events, such as 
production of free oxygen radicals or inflammatory mediators, 
should be combined with molecules that could stimulate 
healing and regeneration. In particular, as pain is recognized 
to be the most bothersome symptom associated with RID, 
particular attention should be paid to its management. The 
investigation in this setting of molecules with an established 
action on localized pain (e.g. carnitine85,86) can be of the 
highest interest.
The need of multiple actions should be, however, weighed 
against the need for limiting risk of adverse events and  
drug–drug interactions, and therefore the minimum  
possible number of components should be included. 
Furthermore, the formulation should be carefully selected:  
for instance, an oily phase may block the penetration of  
the RT beam. Hence, formulations without an oily phase,  
such as gels, may be preferred over those containing this  
(e.g. creams).
Proper selection of vehicle has also a major role, as it may 
influence the penetration into the different skin layers, and 
thereafter the cell targets eventually reached. Liposome 
formulations are able to uniformly penetrate the horny 
layer leading to a 4–14-times higher local concentration of 
active substances compared with conventional emulsions.87 
Moreover, beyond their role as carriers, liposomes can be 
considered as active agents, given their richness  
in phospholipids and omega fatty acids, for the treatment  
of dry, scaly, and flaky skin.87 In an in vitro study, an  
ascorbate phosphatidylcholine liposome was shown  
to overcome the stratum corneum and deliver the active 
agent into the dermis to prevent photodamage.88 These 
findings were mirrored in another experimental  
study.89
Hence, a topical product containing rationally selected 
components able to address pain, skin damage, and the other 
bothersome symptoms of RID – delivered by proper vehicle – 
ensuring, at the same time, optimal chemo-physical properties 
would be of the highest interest in the current treatment 
scenario for RID. Such a compound may be used also in the 
preventive setting, in line with recent suggestions,4 in order to 
limit the onset of RID, improve the quality of life, and reduce 
the risk of RT interruptions.
Box 1. Practical tips for the clinical management of RID.
•	 Wash irradiated skin with lukewarm water and a mild pH, neutral or non-alkaline, soap daily
•	 Shave with a sharp, disinfected wet razor or with non-traumatizing electric razor
•	 Wear loose-fitting clothes in order to prevent friction injuries over the irradiated area 
•	 Avoid extreme temperatures and sun exposure
•	 Avoid the use of metallic-based topical products, perfumes, and the use of tapes and adhesives
•	 Choose a proper topical product for each patient in order to keep the skin hydrated
•	 Any topical product should not be applied over the irradiated skin from 1 to 4 hours before the daily treatment
•	 Consider dressings and advanced medications in case of wet desquamation
•	 Prevent superinfections
•	 Consider topical or systemic antimicrobials in case of infection
•	 In case of grade 3 RID, every effort should be made to try not to interrupt RT
•	 In case of grade 4 RID, consider discontinuation of RT
RID, radiation-induced dermatitis; RT, radiation therapy.
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